Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;24(11):2131-2139.
doi: 10.1002/ejhf.2593. Epub 2022 Jul 12.

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure

Affiliations

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure

Riccardo M Inciardi et al. Eur J Heart Fail. 2022 Nov.

Abstract

Aims: Limited data exist regarding the prognostic relevance of changes in left atrial (LA) dimensions in patients with heart failure (HF). We assessed changes in LA dimension and their relation with outcomes after optimization of guideline-directed medical therapy (GDMT) in patients with new-onset or worsening HF.

Methods and results: Left atrial diameter was assessed at baseline and 9 months after GDMT optimization in 632 patients (mean age 65.8 ± 12.1 years, 22.3% female) enrolled in BIOSTAT-CHF. LA adverse remodelling (LAAR) was defined as an increase in LA diameter on transthoracic echocardiography between baseline and 9 months. After the 9-month visit, patients were followed for a median of 13 further months. LAAR was observed in 247 patients (39%). Larger baseline LA diameter (odds ratio [OR] 0.90; 95% confidence interval [CI] 0.87-0.93; p < 0.001) and up-titration to higher doses of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEi/ARBs) (OR 0.56; 95% CI 0.34-0.92; p = 0.022) were independently associated with lower likelihood of LAAR. LAAR was associated with an increased risk of the composite of all-cause mortality or HF hospitalization (log-rank p = 0.007 and adjusted hazard ratio 1.73, 95% CI 1.22-2.45, p = 0.002). The association was more pronounced in patients without a history of atrial fibrillation (p for interaction = 0.009).

Conclusion: Among patients enrolled in BIOSTAT-CHF, LAAR was associated with an unfavourable outcome and was prevented by ACEi/ARB up-titration. Changes in LA dimension may be a useful marker of response to treatment and improve risk stratification in patients with HF.

Keywords: Guideline-directed medical therapy; Heart failure; Left atrium.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier estimates of all‐cause death or heart failure (HF) hospitalization in patients with and without left atrial (LA) adverse remodelling. Unadjusted hazard ratio (HR) with 95% confidence interval (CI) are shown.
Figure 2
Figure 2
Restricted cubic spline analysis showing the continuous association of change in left atrial (LA) diameter with all‐cause death or heart failure (HF) hospitalization (incident rate per 100 person‐years [py]).

Comment in

Similar articles

Cited by

References

    1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202. - PubMed
    1. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209–16. - PubMed
    1. Khan MS, Memon MM, Murad MH, Vaduganathan M, Greene SJ, Hall M, et al. Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta‐analysis. Eur J Heart Fail. 2020;22:472–85. - PubMed
    1. Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, et al. Left atrial structure and function and clinical outcomes in the general population. Eur Heart J. 2013;34:278–85. - PMC - PubMed
    1. Inciardi RM, Rossi A. Left atrium: a forgotten biomarker and a potential target in cardiovascular medicine. J Cardiovasc Med (Hagerstown). 2019;20:797–808. - PubMed

Publication types

Substances